TITLE

PULMONER HÄ°PERTANSIYONDA MEDÄ°KAL TEDAVÄ°

PUB. DATE
January 2011
SOURCE
Nobel Medicus Journal;Jan-Apr2011, Vol. 7 Issue 1, p5
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
60988231

 

Related Articles

  • The molecular targets of approved treatments for pulmonary arterial hypertension. Humbert, Marc; Ghofrani, Hossein-Ardeschir // Thorax;Jan2016, Vol. 71 Issue 1, p73 

    Until recently, three classes of medical therapy were available for the treatment of pulmonary arterial hypertension (PAH)--prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 (PDE5) inhibitors. With the approval of the soluble guanylate cyclase stimulator riociguat, an...

  • Endothelin receptor antagonists and scleroderma related digital ulcers. Wha-Yong Lee; Faruqi, Shoaib; Morice, Alyn H. // Acta Reumatológica Portuguesa;jan-mar2013, Vol. 38 Issue 1, p58 

    No abstract available.

  • Sildenafil (Viagra) May Help Improve Control of Pulmonary Hypertension. Ghofrani, H.A.; Wiedemann, R.; Rose, F.; Olschewski, H.; Schermuly, R.T.; Weissmann, N.; Seeger, W.; Grimminger, F. // Annals of Internal Medicine;4/2/2002, Vol. 136 Issue 7, pI35 

    Examines the efficacy of sildenafil in the treatment of pulmonary hypertension. Characterization of pulmonary hypertension; Enhancement on the actions of iloprost and nitric oxide; Combination of sildenafil with standard treatments.

  • Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Launay, David; Sitbon, Olivier; Le Pavec, Jérôme; Savale, Laurent; Tchérakian, Colas; Yaïci, Azzedine; Achouh, Lara; Parent, Florence; Jais, Xavier; Simonneau, Gérald; Humbert, Marc // Rheumatology;Mar2010, Vol. 49 Issue 3, p490 

    Objective. Data on long-term efficacy of bosentan, an oral dual ET receptor antagonist, in SSc-associated pulmonary arterial hypertension (SSc-PAH) are lacking. We aimed to describe the long-term outcome of SSc-PAH treated with first-line monotherapy bosentan followed or not by the addition of...

  • Caution needed in treating pulmonary hypertension.  // Patient Care;Sep2004, Vol. 38 Issue 9, p12 

    Discusses research being done on medical therapy for pulmonary atrial hypertension (PAH). Reference to a study by D. B. Badesch et al published in the 2004 issue of "Chest"; Benefits of calcium-channel blockers; Scope of an evidence-based guideline from the American College of Chest Physicians...

  • Iloprost.  // Reactions Weekly;Aug2015, Vol. 1564 Issue 1, p103 

    The article presents case studies of 11 patients, aged 27-75 years, who were diagnosed with central venous catheter-related blood stream infections (CR-BSI) following administration of IV iloprost for pulmonary hypertension.

  • FDA approves epoprostenol for hypertension treatment. Raible, Eric // Cardiology Today;Nov2008, Vol. 11 Issue 11, p26 

    The article reports on the approval given by the U.S. Food and Drug Administration to the use of epoprostenol injection for long-term treatment for patients with primary pulmonary hypertension. The use of the drug is also suggested for pulmonary hypertension associated with the scleroderma...

  • Long-term outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: a single institution experience Saouti, Nabil; Morshuis, Wim J.; Heijmen, Robin H.; Snijder, Repke J. // European Journal of Cardio-Thoracic Surgery;Jun2009, Vol. 35 Issue 6, p947 

    Abstract: Objective: Pulmonary endarterectomy (PEA) for chronic thromboembolic pulmonary hypertension (CTEPH) is the first treatment of choice with good short-term results. Only limited data are available concerning the long-term outcome after PEA. The purpose of this study is to evaluate the...

  • Sildenafil looks safe from an ocular perspective.  // Reactions Weekly;3/3/2012, Issue 1391, p2 

    The article discusses research on the safety and tolerance of sildenafil among patients with pulmonary arterial hypertension (PAH), by B. M. Wirostko and colleagues, published in the "British Medical Journal."

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics